Oncology Pharma, Inc. engages in the development, manufacture and commercialization of therapeutics. The company is headquartered in San Francisco, California. The firm is focused on licensing, developing, manufacturing and commercializing therapeutics. The Company’s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The firm offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Company’s NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.
Oncology Pharma Inc 주요 수익원은 Banking and Related Activities이며, 최신 수익 발표에서 수익은 17,600,540입니다. 지역별로는 United States이 Oncology Pharma Inc의 주요 시장이며, 수익은 17,600,540입니다.